Key result
High-grade solid tumors were associated with a significantly higher risk of symptomatic venous thromboembolism compared with low-grade tumors (HR 2.0; 95% CI 1.1-3.5; P=0.015).
Why the study?
Does high tumor grade increase the risk of symptomatic venous thromboembolism in patients with cancer?
Population
747 patients with newly diagnosed solid tumors or progression of disease after remission
Comparison
High-grade tumors (G3 and G4) vs Low-grade tumors (G1 and G2)
Design
Cohort
Follow-up
median 526 days
Authors
Loading...
May aid VTE risk stratification in cancer; hypothesis-generating for grade-specific prevention trials.
Cohort (n=747)
Does high tumor grade increase the risk of symptomatic venous thromboembolism in patients with cancer?
Hazard Ratio: 2 (95% CI 1.1–3.5)
Absolute Event Rate: 8.2% vs 4%
p-value: p=.015
High tumor grade is significantly associated with an increased risk of symptomatic venous thromboembolism in patients with cancer.
Ahlbrecht et al. (2012) conducted a cohort in Cancer (n=747). High-grade tumors vs. Low-grade tumors was evaluated on Occurrence of symptomatic VTE (HR 2.0, 95% CI 1.1 to 3.5, p=.015). High-grade solid tumors were associated with a significantly higher risk of symptomatic venous thromboembolism compared with low-grade tumors (HR 2.0; 95% CI 1.1-3.5; P=0.015).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: